Jazz Pharmaceuticals ( (JAZZ) ) has issued an announcement.
Jazz Pharmaceuticals has announced that Bruce Cozadd, its Co-Founder, Chairperson, and CEO, will retire from his CEO position by the end of 2025, once a successor is appointed. The company is initiating a formal search to identify a new CEO, considering both internal and external candidates, and Cozadd will continue as Chairperson after stepping down to provide strategic guidance.
More about Jazz Pharmaceuticals
Jazz Pharmaceuticals is a biopharmaceutical company focusing on developing and commercializing innovative medicines, primarily catering to patients with unmet medical needs in areas such as neuroscience and oncology.
YTD Price Performance: 0.03%
Average Trading Volume: 612,940
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $7.44B
See more data about JAZZ stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com